Report cover image

Medullary Thyroid Cancer

Published Jul 01, 2025
Length 281 Pages
SKU # GJOB20171834

Description

Global Medullary Thyroid Cancer Market to Reach US$2.2 Billion by 2030

The global market for Medullary Thyroid Cancer estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Radiation Therapy Treatment segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$383.3 Million While China is Forecast to Grow at 12.1% CAGR

The Medullary Thyroid Cancer market in the U.S. is estimated at US$383.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$468.0 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Medullary Thyroid Cancer Market – Key Trends & Drivers Summarized

What Makes Medullary Thyroid Cancer Unique Among Thyroid Malignancies?

Medullary thyroid cancer (MTC) stands out as a distinct and relatively rare form of thyroid malignancy, accounting for approximately 3 to 4 percent of all thyroid cancer cases worldwide. Unlike the more common papillary and follicular thyroid cancers, which originate from follicular cells, MTC arises from parafollicular C cells that produce the hormone calcitonin. This unique origin gives MTC a different biological behavior, clinical presentation, and treatment approach. MTC can occur sporadically or as part of inherited syndromes such as multiple endocrine neoplasia type 2 (MEN 2), making genetic testing a cornerstone of diagnosis and risk stratification. The presence of elevated calcitonin and carcinoembryonic antigen (CEA) levels serves as important biomarkers for early detection and disease monitoring. Unlike differentiated thyroid cancers, MTC does not typically absorb radioactive iodine, limiting the effectiveness of traditional thyroid cancer therapies. Surgical resection remains the primary curative intervention, often involving total thyroidectomy and lymph node dissection. However, the disease’s propensity for early lymphatic spread and distant metastasis, especially to the liver and lungs, complicates long-term management. Additionally, patients with inherited forms often present at a younger age and may develop other endocrine tumors, further increasing clinical complexity. These factors underscore the need for early diagnosis, tailored treatment strategies, and lifelong monitoring, making MTC one of the most challenging thyroid cancers to manage clinically.

How Are Advances in Molecular Biology and Genetic Testing Reshaping Diagnosis and Risk Assessment?

The understanding of medullary thyroid cancer has been significantly enhanced by advances in molecular biology and genetic testing, which have become integral to both diagnosis and risk assessment. The identification of mutations in the RET proto-oncogene has been a landmark development, particularly in cases associated with familial syndromes such as MEN 2A and MEN 2B. Genetic screening of at-risk individuals allows for early detection and prophylactic thyroidectomy, which has been shown to dramatically improve survival outcomes. In sporadic cases, somatic RET mutations and RAS mutations offer insights into tumor behavior and potential therapeutic responses. The ability to stratify patients based on their genetic profiles has led to more personalized treatment approaches and follow-up protocols. Molecular diagnostics also facilitate differentiation between benign and malignant thyroid nodules when traditional imaging and cytology are inconclusive. Liquid biopsy techniques, though still emerging, show promise for non-invasive monitoring of disease progression and recurrence. These molecular insights are complemented by serum biomarkers such as calcitonin and CEA, which serve as reliable indicators of tumor burden and treatment response. Furthermore, genetic counseling has become a critical component of care for patients with hereditary forms of MTC, allowing for family-wide risk assessment and preventive strategies. As precision medicine continues to evolve, the integration of genetic and molecular data is expected to further refine diagnostic accuracy and improve individualized management for patients with this aggressive form of thyroid cancer.

What Role Do Targeted Therapies and Novel Drugs Play in Changing the Treatment Landscape?

The treatment landscape for medullary thyroid cancer has undergone a transformative shift with the advent of targeted therapies and novel drug development. For patients with advanced, inoperable, or metastatic MTC, traditional chemotherapy and radiotherapy offer limited efficacy, prompting a search for more effective systemic treatments. Tyrosine kinase inhibitors (TKIs) such as vandetanib and cabozantinib have emerged as the frontline therapies in such cases, particularly for patients with progressive disease. These agents work by inhibiting RET and other pathways involved in tumor growth and angiogenesis, offering prolonged progression-free survival and disease control. More recently, highly selective RET inhibitors like selpercatinib and pralsetinib have demonstrated significant clinical benefits with fewer off-target effects, especially in patients with RET-mutant tumors. These drugs represent a significant advancement in precision oncology, as they allow clinicians to match treatment with a patient’s specific genetic alterations. Ongoing clinical trials are exploring combination therapies, immunotherapies, and other novel agents aimed at overcoming resistance to current treatments. Despite these advances, treatment side effects and the risk of eventual disease progression remain challenges, necessitating continuous monitoring and adjustment of therapeutic strategies. Additionally, access to these therapies can vary based on healthcare infrastructure and insurance coverage, influencing outcomes in different regions. As research continues to expand the arsenal of targeted treatments, the outlook for patients with advanced MTC is improving, though long-term management still requires a careful balance of efficacy, safety, and quality of life considerations.

What Are the Key Drivers Fueling Growth and Innovation in the Medullary Thyroid Cancer Market?

The growth in the medullary thyroid cancer market is driven by several intersecting forces related to diagnostic innovation, drug development, patient awareness, and healthcare infrastructure expansion. First, increased use of routine neck ultrasounds and fine-needle aspiration biopsies has led to earlier detection of thyroid nodules, some of which are identified as MTC through follow-up molecular and biochemical testing. Second, rising awareness of genetic syndromes like MEN 2 among physicians and the public has led to greater demand for genetic counseling and early screening in high-risk families. Third, ongoing advances in genomics and precision medicine are fueling the development of targeted therapies that improve survival outcomes and offer new hope to patients with advanced disease. Fourth, investment by pharmaceutical companies in orphan drug development is incentivizing research and commercialization of therapies for rare cancers like MTC, resulting in a more robust treatment pipeline. Fifth, the proliferation of digital health tools and patient advocacy platforms is enabling individuals to access second opinions, participate in clinical trials, and better manage their care. Sixth, expanding access to healthcare in emerging economies is gradually improving diagnosis and treatment rates, although disparities still exist. Seventh, regulatory support through fast-track designations and orphan drug approvals is accelerating the time to market for new treatments. Lastly, multidisciplinary care models integrating endocrinology, oncology, genetics, and surgery are enhancing patient outcomes through coordinated and comprehensive care. These drivers collectively support a growing and increasingly sophisticated market focused on improving diagnosis, treatment, and quality of life for patients affected by medullary thyroid cancer.

SCOPE OF STUDY:

The report analyzes the Medullary Thyroid Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment (Surgery Treatment, Radiation Therapy Treatment, Chemotherapy Treatment); End-Use (Hospitals End-Use, Radiation Therapy Center End-Use, Cancer Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -
  • AstraZeneca PLC
  • Bayer AG
  • BeOne Medicines
  • Blueprint Medicines
  • Crinetics Pharmaceuticals
  • Eli Lilly and Company
  • Epizyme, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • GSK (GlaxoSmithKline)
  • Ipsen
  • Janssen (Johnson & Johnson)
  • Jiangsu Hengrui Medicine
  • Loxo Oncology (Eli Lilly subsidiary)
  • Millennium Pharmaceuticals (Takeda)
  • Novo Nordisk
  • Pfizer Inc.
  • Rigel Pharmaceuticals
  • Sanofi AG
  • Takeda Pharmaceutical Company
AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Table of Contents

281 Pages
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Medullary Thyroid Cancer – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Awareness and Early Diagnosis Efforts Throw the Spotlight on Medullary Thyroid Cancer Detection Pathways
Advances in Genetic Screening Propel Growth in RET Mutation Testing and Targeted Therapy Eligibility
Increased Incidence of Sporadic and Hereditary MTC Expands the Addressable Market Opportunity for Targeted Therapeutics
Approvals of RET Inhibitors Strengthen the Business Case for Precision Medicine in MTC Management
Expansion of Next-Generation Sequencing (NGS) in Oncology Accelerates Demand for Molecular Diagnostic Solutions
Unmet Needs in Late-Stage and Metastatic MTC Drive Clinical Interest in Novel Combination Therapies
Growing Role of Multidisciplinary Care Models Sustains Demand for Coordinated Treatment Planning Tools
Tele-oncology and Remote Monitoring Trends Enhance Access to Specialist Care for MTC Patients in Underserved Regions
Pharmaceutical Innovation in Kinase Inhibitors Generates New Hope for Progressive or Refractory MTC Cases
Increased Use of Biomarkers like Calcitonin and CEA Drives Growth in Longitudinal Monitoring Solutions
Global Expansion of Cancer Genomics Programs Opens New Pathways for MTC Identification and Stratified Treatment
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Medullary Thyroid Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Medullary Thyroid Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Radiation Therapy Center End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Radiation Therapy Center End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Radiation Therapy Center End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Cancer Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 24: USA Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 25: USA 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 28: USA 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
CANADA
TABLE 29: Canada Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 31: Canada 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 32: Canada Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 34: Canada 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
JAPAN
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 35: Japan Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 37: Japan 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 38: Japan Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 40: Japan 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
CHINA
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 41: China Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: China Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 43: China 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 44: China Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 46: China 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
EUROPE
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 47: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Medullary Thyroid Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 49: Europe 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 52: Europe 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 55: Europe 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
FRANCE
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 56: France Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: France Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 58: France 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 59: France Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 61: France 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
GERMANY
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 62: Germany Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 64: Germany 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 65: Germany Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 67: Germany 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
ITALY
TABLE 68: Italy Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 70: Italy 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 71: Italy Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 73: Italy 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
UNITED KINGDOM
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 74: UK Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: UK Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 76: UK 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 77: UK Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 79: UK 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
SPAIN
TABLE 80: Spain Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Spain Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 82: Spain 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 83: Spain Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 85: Spain 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
RUSSIA
TABLE 86: Russia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Russia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 88: Russia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 89: Russia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 91: Russia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 94: Rest of Europe 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Medullary Thyroid Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 100: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
AUSTRALIA
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 107: Australia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Australia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 109: Australia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 110: Australia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 112: Australia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
INDIA
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 113: India Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: India Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 115: India 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 116: India Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: India Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 118: India 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 119: South Korea Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: South Korea Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 121: South Korea 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 122: South Korea Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Rest of Asia-Pacific Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
LATIN AMERICA
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 131: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 132: Latin America Historic Review for Medullary Thyroid Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 133: Latin America 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 134: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 140: Argentina Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Argentina Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 142: Argentina 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 143: Argentina Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
BRAZIL
TABLE 146: Brazil Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Brazil Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 148: Brazil 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 149: Brazil Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
MEXICO
TABLE 152: Mexico Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Mexico Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 154: Mexico 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 155: Mexico Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Rest of Latin America Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 160: Rest of Latin America 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
MIDDLE EAST
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 164: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 165: Middle East Historic Review for Medullary Thyroid Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 166: Middle East 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 167: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
IRAN
TABLE 173: Iran Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Iran Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 175: Iran 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 176: Iran Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 178: Iran 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
ISRAEL
TABLE 179: Israel Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Israel Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 181: Israel 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 182: Israel Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 184: Israel 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Saudi Arabia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 187: Saudi Arabia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 191: UAE Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: UAE Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 193: UAE 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 194: UAE Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 196: UAE 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: Rest of Middle East Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 199: Rest of Middle East 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
AFRICA
Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 203: Africa Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Africa Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 205: Africa 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
TABLE 206: Africa Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 208: Africa 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
IV. COMPETITION
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.